CIPLA · NSE
Cipla Limited
₹1,394.5
+1.32% (+₹18.2)
Prev. close
₹1,376.3
Volume
13,86,584
Delivery %
68.0%
As of
18 Sept 2026
Price history
Citi Analysis · Citigroup Inc. · 26 Aug 2026
“Maintained 'Buy' rating on Cipla with a target price of ₹1,700, implying a 20.1% upside from Tuesday's closing price of ₹1,415. Citi expects the latest USFDA observations at the Pithampur facility to have no impact on near- to medium-term earnings, as key pipeline approvals are linked to other facilities. A resolution of regulatory issues at Pithampur would be a significant longer-term positive for managing key respiratory product supplies.”
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Maintained 'Buy' rating on Cipla with a target price of ₹1,700, implying a 20.1% upside from Tuesday's closing price of …” | Citi AnalysisCitigroup Inc. | Cipla | PENDING | ||||
“Maintained 'Buy' rating on Cipla with a target price of ₹1,700, implying a 20.1% upside from Tuesday's closing price of ₹1,415. Citi expects the latest USFDA observations at the Pithampur facility to have no impact on near- to medium-term earnings, as key pipeline approvals are linked to other facilities. A resolution of regulatory issues at Pithampur would be a significant longer-term positive for managing key respiratory product supplies.” This call hasn't reached its evaluation window yet — the verdict will appear here once it's graded. | |||||||
Fundamentals
About Cipla Limited
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Achin Gupta
Headquarters
Mumbai
Employees
31,369
Website
cipla.comExchange
View on NSE ↗Key stats
Market cap
₹1.11 L Cr
P/E ratio (TTM)
33.0
Dividend yield
0.96%
EPS (TTM)
₹41.69
Beta (1Y · daily vs NIFTY 50)
0.63
Beta (5Y · monthly vs NIFTY 50)
0.67
Shares float
56.97 Cr
EPS · quarter ended Jun 2026
₹9.76
Upcoming earnings
29 Oct 2026
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹19,159.59 Cr | ₹21,763.34 Cr | ₹22,753.12 Cr | ₹25,774.09 Cr | ₹27,547.62 Cr | ₹28,162.59 Cr | |
| EBITDA | ₹4,518.42 Cr | ₹4,651.57 Cr | ₹5,152.10 Cr | ₹6,842.80 Cr | ₹7,860.28 Cr | ₹6,355.48 Cr |
| ₹2,404.87 Cr | ₹2,516.75 Cr | ₹2,801.91 Cr | ₹4,121.55 Cr | ₹5,272.52 Cr | ₹3,879.23 Cr | |
| Diluted EPS | ₹29.79 | ₹31.17 | ₹34.69 | ₹51.01 | ₹65.24 | ₹48 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹25,151.89 Cr | ₹27,101.12 Cr | ₹29,463.28 Cr | ₹32,533.00 Cr | ₹37,334.00 Cr | ₹42,343.00 Cr | |
| ₹2,014.41 Cr | ₹1,055.78 Cr | ₹803.12 Cr | ₹559.41 Cr | ₹438.19 Cr | ₹613.77 Cr | |
| Stockholders' equity | ₹18,326.53 Cr | ₹20,841.69 Cr | ₹23,407.78 Cr | ₹26,706.00 Cr | ₹31,194.00 Cr | ₹34,432.00 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹3,755.20 Cr | ₹3,325.90 Cr | ₹3,238.00 Cr | ₹4,134.00 Cr | ₹5,005.00 Cr | ₹3,940.00 Cr | |
| Investing cash flow | ₹-2,387.18 Cr | ₹-1,871.88 Cr | ₹-2,388.51 Cr | ₹-2,988.03 Cr | ₹-3,691.14 Cr | ₹-2,326.13 Cr |
| ₹-1,329.90 Cr | ₹-1,599.79 Cr | ₹-958.29 Cr | ₹-1,200.43 Cr | ₹-1,292.79 Cr | ₹-1,233.65 Cr | |
| Capital expenditure | ₹-818.92 Cr | ₹-701.15 Cr | ₹-1,183.00 Cr | ₹-1,349.00 Cr | ₹-1,548.00 Cr | ₹-3,079.00 Cr |
| End cash position | ₹793.29 Cr | ₹658.11 Cr | ₹561.33 Cr | ₹512.34 Cr | ₹542.65 Cr | ₹1,015.39 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22 | Jun 22–Dec 22(3Q) | Mar 23 | Jun 23–Mar 24(4Q) | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25–Jun 26(4Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 36.12% | 36.11% | 33.63% | 33.61% | 33.55% | 33.47% | 30.91% | 30.92% | 29.19% | 29.20% | 29.19% | 29.21% |
| Public | 63.88% | 63.89% | 66.37% | 66.39% | 66.45% | 66.53% | 69.09% | 69.08% | 70.81% | 70.80% | 70.81% | 70.79% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Aurobindo Pharma Limited | ₹97,238.87 Cr | ₹1,734 | 26.4 | 2.57 | 9.2% | 0.21 | +6.4% | +53.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Concall transcripts
Show all 13
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
57 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Pharma sector stocks down today, September 2: Aarti Drugs falls 1.90%, Cipla down 1.18%, Panacea Biotec drops 0.73%
Business Upturn · 17 days ago
Sensex jumps nearly 300 points; ICICI Bank, Eternal surge while Cipla, Tata Steel fall
Cipla Limited's stock fell approximately 1% after the US Food and Drug Administration issued seven observations following an inspection of its Pithampur facility. This decline occurred as Indian equity benchmarks generally rose, supported by falling crude oil prices. The broader market saw gains in banking stocks like ICICI Bank.